August 30, 2014
Why is a payday loan right for you Payday loan 50 up to
Payday loans uk

Barriers to Treatment Use

Posted on August 27, 2014 by in LifeGuide, Treatment Horizons

LifeGuide [Treatment Horizons] Opening Doors A new survey uncovers barriers to treatment by Chael Needle There’s an old chestnut that goes something like this: People won’t make a change until they want to make a change. In our present context of low treatment rates, change—linking to and staying in care for those aware of their [...]

HIV Therapeutic Vaccine Advances

Posted on July 24, 2014 by in LifeGuide, Treatment Horizons

Treatment Horizons Another Kind of Morning HIV therapeutic vaccines try to come of age by Mariel Selbovitz, MPJ, and David Miller Despite over three decades of research on therapeutic vaccines for the treatment of HIV, clinical advances have been slow in coming for this important class of drug. While there are a plethora of therapeutic [...]

New Treatment Guidelines

Posted on June 23, 2014 by in LifeGuide, Treatment Horizons

LifeGuide [Treatment Horizons] New Guidelines Revised treatment strategies address cost, monitoring & choosing a regimen by Chael Needle Revised guidelines for HIV treatment approaches will help you and your physician figure out how to fine-tune your regimen, now or when you might need to do so in the future. Reported in Guidelines for the Use [...]

Editing Genes for a Cure

Posted on April 11, 2014 by in LifeGuide, Treatment Horizons

Close to the Edit A functional cure candidate modifies genes to create HIV-resistant cells by Chael Needle Gary Blick, MD, AAHIVS, Medical & Research Director of CIRCLE CARE Center and Chief Medical Officer of World Health Clinicians, doesn’t throw the word “cure” around lightly. As an HIV physician for over thirty years, he remembers when [...]

Mighty Mouse

Posted on March 20, 2014 by in LifeGuide, Treatment Horizons

Mighty Mouse A humanized BLT mouse model creates a vital platform for drug discovery by Chael Needle In the early stages of drug discovery, many candidates that show promise of effective anti-HIV activity may be in the running. But which ones deserve to move on? That question is answered in part by those researchers who [...]

Host Restrictive Factors

Posted on March 5, 2014 by in LifeGuide, Treatment Horizons

The Deeper End of the Ocean Host restrictive factors create research excitement by Mariel Selbovitz, MPH, and David Miller The doors on viral host restrictive factors (HRFs), the means by which our cells are designed to resist infection, are being pried open by scientists who see the next round of therapeutic advances for treating HIV [...]

HPV Immunotherapy Research

Posted on January 13, 2014 by in LifeGuide, Treatment Horizons

Warts & All An immunotherapy candidate seeks to address complications from HPV by Chael Needle Human papillomavirus (HPV) is the most common sexually transmitted infection, but, according to the CDC, most who are infected never develop symptoms nor health problems. Keep in mind, though: a history of anogenital warts in men and women has been [...]

Introducing Dolutegravir

Posted on September 19, 2013 by in LifeGuide, Treatment Horizons

Treatment Horizons by Chael Needle Surpassing Expectations ViiV Healthcare introduces its first FDA-approved agent ViiV Healthcare is exclusively devoted to the treatment of HIV disease, and the singular focus is arguably paying off. Tivicay (dolutegravir) is the first drug out of the ViiV Healthcare pipeline to be FDA-approved. The integrase strand transfer inhibitor is indicated [...]

AGS-004 Immunotherapy

Posted on August 23, 2013 by in LifeGuide, Treatment Horizons

Treatment Horizons by Chael Needle Fully Personalized An immunotherapy candidate stimulates T-cell responses via patient-specific antigens Previous studies have established immunotherapy candidate AGS-004, both as a single agent and in concert with antiretrovirals, to be safe and well-tolerated, lacking toxicity, and, importantly, as conferring an effective immune response—an atypically long delay in viral rebound and [...]

Safety Net

Posted on June 17, 2013 by in LifeGuide, Treatment Horizons

Treatment Horizons by Chael Needle A nonprofit creates a new support system for the uninsured Joining Merck and ViiV Healthcare, Gilead Sciences is now supporting and participating in a new patient assistance program (PAP) that provides individuals living with HIV/AIDS and in treatment with a singular portal to free medications. Launched in the summer of [...]